NCT05428358Recruiting
Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery
Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery (MAGIPAC): A Randomized Clinical Trial.
Source: ClinicalTrials.gov · Last updated 29 Apr 2026
Brief summary (registry, in English)
The aim of the study is to examine the incremental value of using magnetic resonance imaging (MRI) in addition to computed tomography (CT) in the diagnostic workup of pancreatic cancer patients.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- First submitted
- 16 Jun 2022
- Start date
- 30 Aug 2022
- Primary completion date
- 1 Dec 2027
- Lead sponsor
- University of Aarhus
- Diseases
- Pancreatic cancer
- NCT number
- NCT05428358
What you commit to
- Study type: Interventional
- Planned participants: 200
- From 30 Aug 2022 to the primary completion date, 1 Dec 2027
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior receipt of neoadjuvant chemotherapy or downstaging/-sizing treatment
- Comorbidity rendering major surgery unfeasible (inoperable)
Other illness
- Metastatic disease
Lab values
- Unable to undergo MRI (Kidney insufficiency (eGFR \< 60 ml/min/1.73 m2 body surface ar-ea); Claustrophobia; Cardiac pacemaker)
Other
- No informed consent
- Postoperative histology other than adenocarcinoma of pancreato-biliary origin.
- MRI with liver-specific contrast performed during standard workup.
Who the study is looking for
- Pancreatic cancer patients considered to have a locally resectable or borderline resectable tumor by the local hepato-pancreato-biliary multidisciplinary team board
- No liver metastases on CT
- At least 18 years old and able to provide informed consent
- Expected pancreatic ductal adenocarcinoma based on CT scan
Age in the registry: 18 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Aalborg University Hospital Coordinator of this site? Confirm its status | Aalborg | Denmark | Recruiting |
| Aarhus University Hospital Coordinator of this site? Confirm its status | Aarhus | Denmark | Recruiting |
| Rigshospitalet Coordinator of this site? Confirm its status | Copenhagen | Denmark | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.